Estimated long-term benefits of finerenone in heart failure
www.eurekalert.org
About The Study: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone was estimated to extend event-free survival by up to 3 years among people with heart failure with mildly reduced or preserved ejection fraction. 
This is an automated archive made by the Lemmit Bot.

The original was posted on /r/science by /u/FunnyGamer97 on 2024-09-29 04:16:11+00:00.

Original Title: Study: Long-term treatment with nonsteroidal mineralocorticoid receptor antagonist finerenone estimated to extend event-free survival by up to 3 years among people with heart failure with mildly reduced or preserved ejection fraction.